The sale of the diabetes care business, initially announced on April 22, 2025, has now been completed. This is a strategic milestone for Ypsomed as it refocuses on its market-leading position in subcutaneous self-injection solutions for pharmaceutical and biotech companies.

The company also confirms the usual transitional service agreements and certain contract manufacturing services will remain in effect following the transaction closing, ensuring continuity of services and a smooth transition.